Physician profile
Mingwu Wang
NPI 1841497765
$5,390.57
in general payments reported to CMS, 2019-2025
20 companies · $1,024 in 2025
The $1,024 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $967 · 2020: $327 · 2021: $456 · 2022: $794 · 2023: $429 · 2024: $1,393 · 2025: $1,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,128 · Honoraria: $600 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,127.62 |
| Honoraria | $600.00 |
| Education | $117.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $1,033.23 | 2019-2025 | Idose, Photrexa Viscous and Photrexa, Kxl System (Not Refurbished) |
| Harrow Eye, LLC | $934.79 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $899.41 | 2019-2023 | |
| Dompe US, INC. | $629.05 | 2019-2025 | Oxervate |
| Alcon Vision LLC | $507.47 | 2020-2025 | Tryptyr, Clareon Panoptix Pro, Clareon |
| Bausch & Lomb Americas INC. | $288.86 | 2022-2025 | Xiidra, Miebo |
| Mallinckrodt Hospital Products INC. | $170.89 | 2024-2025 | Acthar |
| Tarsus Pharmaceuticals, INC. | $165.81 | 2024-2025 | Xdemvy |
| Allergan, INC. | $160.67 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $159.80 | 2019 | |
| Ivantis, INC | $146.30 | 2021 | |
| Kala Pharmaceuticals, INC. | $73.98 | 2019-2021 | |
| Biotissue Holdings INC. | $54.94 | 2024 | |
| Oyster Point Pharma, INC. | $37.12 | 2024 | Ryzumvi, Tyrvaya |
| Eyevance Pharmaceuticals LLC | $33.92 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $29.93 | 2021-2023 | Dextenza |
| Horizon Therapeutics Plc | $18.53 | 2023 | Tepezza |
| Thea Pharma INC. | $18.48 | 2022 | |
| Sight Sciences, INC. | $13.89 | 2020 | |
| Shire North American Group INC | $13.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mingwu Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.